EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study

Rylee McGonigle, Huseyin Naci iD, Maximilian Siebert iD, Michelle Ouvina iD, Alba Gutiérrez-Sacristán iD, Anita K Wagner, Florence T Bourgeois iD

PLOS Medicine · 17.12.2025 · 22 (12) · e1004651

DOI: 10.1371/journal.pmed.1004651 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS Medicine, online erschienen am 17.12.2025. Verfasst von Rylee McGonigle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Labeling, Drug Approval, Pediatrics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Arnold Ventures, Burroughs Wellcome Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The U.S. Food and Drug Administration (FDA) has the authority to require that sponsors conduct pediatric studies for certain new drugs under the Pediatric Research Equity Act (PREA). Here, we evaluate the characteristics and completion of these studies and assess the addition of pediatric-specific evidence generated from these studies into drug labeling. Methods and findings We performed a retrospective cohort study of all novel drugs approved by the FDA from 2011 to 2023 with at least one pediatric study requirement issued under PREA. Study status and outcomes were followed through 31 December 2024. We assessed completion of pediatric studies; addition of pediatric prescribing information to drug labels; and deviations from FDA-projected timelines. Of 552 novel drugs approved by the FDA between 2011 and 2023, 179 (32.4%) were subject to pediatric study requirements under PREA. Thirteen were later discontinued, resulting in a final cohort of 166 drugs and 338 pediatric study requirements. About half (51.8%) of the studies assessed efficacy. Among 222 studies with due dates by 31 December 2024, only 24.3% were completed by the original deadline. Over half (56.8%) received extensions of original timelines, by an average of 2.9 years (SD 2.0). At 10 years after drug approval, while 92.0% of studies were expected to have been completed, 59.5% had been completed. Of the 117 drugs with studies due by 31 December 2024, 54.7% ( n = 64) had pediatric labeling updated with results from required studies. The mean time to addition of pediatric approval was 5.7 years (SD 2.6), whereas labeling additions reflecting lack of pediatric safety or benefit took an average of 8.3 years (SD 3.3) ( p < 0.001). While 90.4% of drugs were expected to have all pediatric studies completed by 10 years, only 52.8% had any labeling changes reflecting data from the PREA-mandated studies. A limitation of this study is that publicly available FDA data provide limited detail on study design, execution, and reasons for delays, preventing assessment of study rigor and the factors contributing to delayed completion.

Conclusions

PREA was implemented to advance pediatric drug research and fill a critical gap in pediatric labeling of new drugs. However, our findings reveal frequent delays in study completion and labeling updates, with just over half of labeling additions completed 10 years after drug approval. Strengthening reporting requirements and expanding the FDA’s enforcement authority are essential to ensuring that children receive timely access to safe and effective therapies supported by high-quality evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrug LabelingDrug ApprovalPediatricsHumansUnited StatesRetrospective StudiesChild

Autor:innen und Institutionen

  • Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Pediatric Therapeutics and Regulatory Science Initiative, Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, United States of America.
  • Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
  • Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States of America.
  • Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America.

ORCID-Profile: Huseyin Naci, Maximilian Siebert, Michelle Ouvina, Alba Gutiérrez-Sacristán, Florence T Bourgeois

Förderung

  • Arnold Ventures
  • Burroughs Wellcome Fund

Zitieren

APA

McGonigle, R., Naci, H., Siebert, M., Ouvina, M., Gutiérrez-Sacristán, A., Wagner, A. K., & Bourgeois, F. T. (2025). Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study. PLOS Medicine, 22(12), e1004651. https://doi.org/10.1371/journal.pmed.1004651

Vancouver

McGonigle R, Naci H, Siebert M, Ouvina M, Gutiérrez-Sacristán A, Wagner AK, et al. Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study. PLOS Medicine. 2025;22(12):e1004651. doi:10.1371/journal.pmed.1004651

BibTeX
@article{McGonigle2025,
  author = {McGonigle, Rylee and Naci, Huseyin and Siebert, Maximilian and Ouvina, Michelle and Gutiérrez-Sacristán, Alba and Wagner, Anita K and Bourgeois, Florence T},
  title = {Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study},
  journal = {PLOS Medicine},
  year = {2025},
  volume = {22},
  number = {12},
  pages = {e1004651},
  doi = {10.1371/journal.pmed.1004651}
}
Kostenlos starten →